Connection

GUILLERMINA LOZANO to Cell Transformation, Neoplastic

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Cell Transformation, Neoplastic.
  1. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.316
  2. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010 Sep 15; 70(18):7148-54.
    View in: PubMed
    Score: 0.199
  3. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev. 2007 Feb; 17(1):66-70.
    View in: PubMed
    Score: 0.155
  4. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19842-7.
    View in: PubMed
    Score: 0.154
  5. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72.
    View in: PubMed
    Score: 0.134
  6. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. Cancer Res. 2022 05 16; 82(10):1926-1936.
    View in: PubMed
    Score: 0.112
  7. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res. 2016 08 01; 22(15):3876-83.
    View in: PubMed
    Score: 0.073
  8. Inhibition of the mutant p53 gene in transformation assays. J Surg Res. 1992 Apr; 52(4):401-5.
    View in: PubMed
    Score: 0.056
  9. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991 Sep 11; 19(17):4747-52.
    View in: PubMed
    Score: 0.054
  10. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31; 249(4972):1049-51.
    View in: PubMed
    Score: 0.050
  11. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol. 2007 Aug; 27(15):5479-85.
    View in: PubMed
    Score: 0.040
  12. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005 Jun 10; 331(3):834-42.
    View in: PubMed
    Score: 0.035
  13. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.033
  14. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis. 2004 Feb; 25(2):157-67.
    View in: PubMed
    Score: 0.031
  15. p53 sends nucleotides to repair DNA. Nature. 2000 Mar 02; 404(6773):24-5.
    View in: PubMed
    Score: 0.024
  16. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.016
  17. Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death Differ. 2013 May; 20(5):732-43.
    View in: PubMed
    Score: 0.015
  18. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
    View in: PubMed
    Score: 0.013
  19. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30.
    View in: PubMed
    Score: 0.012
  20. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007 Jul; 117(7):1893-901.
    View in: PubMed
    Score: 0.010
  21. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 1994 Oct; 14(10):6858-67.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.